← Back to Search


Open Label Extension for Pulmonary Hypertension (REBUILD Trial)

Phase 3
Waitlist Available
Research Sponsored by Bellerophon Pulse Technologies
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up baseline to month 4
Awards & highlights


This trial is testing the safety and effectiveness of a drug called inhaled nitric oxide in people at risk for pulmonary hypertension associated with pulmonary fibrosis. The trial is divided into two parts.

Eligible Conditions
  • Pulmonary Hypertension
  • Pulmonary Fibrosis


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to month 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to month 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events and Serious Adverse Events with Long Term INOpulse Therapy
Change in Moderate to Vigorous Physical Activity (MVPA) as Measured by Actigraphy
Secondary outcome measures
Change in 6 Minute Walk Distance
Change in Overall Activity as Measured by Actigraphy
Change in St. George Respiratory Questionnaire (SGRQ) - Activity, Impacts & Total
+4 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Open Label ExtensionExperimental Treatment1 Intervention
Pulsed inhaled iNO 45 mcg/kg IBW/hr
Group II: Inhaled Nitric Oxide (iNO)Active Control1 Intervention
Pulsed inhaled iNO 45 mcg/kg Ideal Body Weight (IBW)/hour (hr)
Group III: PlaceboPlacebo Group1 Intervention
Pulsed inhaled N2, 99.999% gas

Find a Location

Who is running the clinical trial?

Bellerophon Pulse TechnologiesLead Sponsor
6 Previous Clinical Trials
659 Total Patients Enrolled
Edward Parsley, DOStudy DirectorBellerophon Therapeutics
2 Previous Clinical Trials
208 Total Patients Enrolled
Dominique DuchesneStudy DirectorHead Clinical Operations
~32 spots leftby Jul 2025